Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Neoplasms 3Respiratory Tract Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Cancer 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × efatutazone × Clear all
NCT01199068 2021-05-13

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
15 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT00408434 2020-10-19

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

Daiichi Sankyo

Phase 1 Completed
32 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT00881569 2020-09-28

Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017

Daiichi Sankyo

Phase 1 Completed
2 enrolled 9 charts

Advanced Cancer

NCT01199055 2020-07-07

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
16 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡